Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Catalyst-rich medical technology trade: FDA 510(k) clearance on 2026-08-10, CMS NTAP reimbursement support on 2026-08-03, Q2 revenue growth of about 33% and raised full-year revenue guidance helped drive a 24% 21-day breakout.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Persistent Losses ⢠Negative Cash Flow CBLL has strong liquidity and low leverage, but persistent losses, cash burn, declining equity, and a premium valuation make it a high-risk investment pending operating improvement.
Price Behavior
Key Price Behavior Insights: ⢠Range-bound trading ⢠Firm support zone ⢠Resistance rejection Support Level: $23.37â$23.63 Resistance Level: $25.00â$25.04 CBLL was range-bound over the last month, holding above $23.37â$23.63 support but fading from $25.04 resistance; a breakout above $25.04 is bullish, while a break below $23.37 weakens the setup.
Sentiment & News
Key News Insights: ⢠BlackRock New Stake ⢠BofA Holding Increase ⢠Institutional Interest BlackRock's new 5.1% stake and Bank of America's increased holding signal strengthening institutional interest in CeriBell.
AI Summary
CBLL's FDA/NTAP-enabled expansion into a broader point-of-care neurology platform strengthens growth potential, but at ~7x sales the investment hinges on proving that rising hospital utilization converts its 92% gross margins into operating leverage and sharply lower cash burn; investors should wait for sustained expense discipline and free-cash-flow improvement.
Description
CeriBell, Inc. develops point-of-care EEG technology that uses AI to support detection and management of neurological conditions in acute care settings. Its Ceribell System pairs a bedside EEG platform with disposable headbands and portable recorders to enable rapid monitoring outside traditional neurodiagnostic labs. The company was incorporated in 2014, changed its name from Brain Stethoscope, Inc. in 2015, and is based in Sunnyvale, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 14 | Aug 21 | CBLL | CeriBell, Inc. | Catalyst-rich medical technology trade: FDA 510(k) clearance on 2026-08-10, CMS NTAP reimbursement support on 2026-08-03, Q2 revenue growth of about 33% and raised full-year revenue guidance helped drive a 24% 21-day breakout. | Closed | +3.7% |
| Dec 12 | Dec 19 | CBLL | CeriBell, Inc. | Ceribell is a hot idea fueled by recent FDA 510(k) approvals for neurological devices, strong 31% YoY revenue growth, expanding market penetration, positive technical momentum with a 27% price rise, and favorable healthcare sector dynamics supporting near-term appreciation potential. | Closed | +1.2% |